NCT04840784 is a Phase 1 clinical trial of ETH-155008 in NHL, sponsored by Shengke Pharmaceuticals Pty Ltd.

Who is sponsoring NCT04840784?

NCT04840784 is sponsored by Shengke Pharmaceuticals Pty Ltd.

What drugs are being tested in NCT04840784?

Interventions in NCT04840784: ETH-155008.

What condition does NCT04840784 study?

NCT04840784 studies NHL, Leukemia.

Is NCT04840784 still recruiting?

NCT04840784 is currently terminated. Last updated 11 October 2023.

Last reviewed 2023-10-11 · How we verify

NCT04840784

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Terminated Phase 1 Last updated 11 October 2023

What this trial tests

Phase 1 trial testing ETH-155008 in NHL in 9 participants. Terminated before completion.

Timeline

29 June 2021

Primary endpoint
2 May 2023

2 May 2023

Quick facts

Lead sponsor	Shengke Pharmaceuticals Pty Ltd
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	29 June 2021
Primary completion	2 May 2023
Estimated completion	2 May 2023
Sites	5 locations across Australia

Drugs / interventions tested

ETH-155008 — full drug profile →

Conditions studied

NHL — all drugs for NHL →
Leukemia — all drugs for Leukemia →

Sponsor

Shengke Pharmaceuticals Pty Ltd — full company profile →

Who can join

Adults 18 to 80, any sex, with NHL or Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Trial is a FIH, open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with R/R B-cell NHL, CLL/SLL and AML who previously received standard treatment or are ineligible for standard treatment options.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting Pim kinases in hematological cancers: molecular and clinical review.
Bellon M, Nicot C. · · 2023 · cited 58× · PMID 36694243 · DOI 10.1186/s12943-023-01721-1

Verify or expand the search:

Other recruiting trials for NHL

Currently open trials in the same condition.

NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting
NCT06731699 — A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS · Phase 1 · recruiting
NCT06119685 — IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers · Phase 1, PHASE2 · recruiting
NCT04440436 — Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients · Phase 1, PHASE2 · recruiting
NCT03789240 — Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04840784 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shengke Pharmaceuticals Pty Ltd
Last refreshed: 11 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04840784.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing